PDS Biotech Publishes VERSATILE-002 Phase 2 Data in JAMA Oncology: 39.3-Month Median OS in HPV16+ Head and Neck Cancer
PDSB has more than doubled off its 52-week low of $0.195.
Summary
PDS Biotech announced publication of VERSATILE-002 Phase 2 results in JAMA Oncology showing 39.3-month median overall survival for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer, roughly double the standard-of-care benchmark.
Key Events · Product Development and Regulatory · PDSB
-
JAMA Oncology Publication
VERSATILE-002 Phase 2 results published in the September 17, 2026 issue of JAMA Oncology, a peer-reviewed journal of the American Medical Association.
-
39.3-Month Median Overall Survival
In ICI-naïve patients with CPS ≥ 1 (n=53), median overall survival was 39.3 months (95% CI, 23.9 to NE), versus 17.9 months for standard-of-care pembrolizumab or pembrolizumab plus chemotherapy.
-
ORR Nearly Doubles Standard of Care
Objective response rate was 36% by investigator review (5/53 complete responders) and 34% by central review (6/53 complete responders), versus 19% published for pembrolizumab alone.
-
Favorable Safety Profile
Grade ≥3 treatment-related adverse events were 13.8% with no Grade 5 events, compared to 17% for standard-of-care pembrolizumab.
Analysis · PDSB · Life Sciences
Peer-reviewed publication of the VERSATILE-002 Phase 2 trial in JAMA Oncology provides independent validation of PDS0101's efficacy in HPV16-positive recurrent/metastatic head and neck cancer. The 39.3-month median overall survival in ICI-naïve patients with CPS ≥ 1 more than doubles the 17.9-month benchmark for standard-of-care pembrolizumab, and the 36% objective response rate nearly doubles the 19% published for pembrolizumab alone. This matters because PDS0101 is the asset the company is actively seeking to partner or out-license, and strong peer-reviewed data strengthens its negotiating position with potential partners like NantWorks, which holds a one-year exclusive negotiation right. The publication also supports the company's strategic pivot to PDS0301 by demonstrating the value of its legacy asset, potentially unlocking non-dilutive capital through a partnership.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.1M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.